Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Arcus Phase 2 EDGE-Gastric trial in upper GI cancers completed, 332 enrolledOct 26Trial updateArcus Biosciences, Inc.domvanalimab
Arcus Biosciences closes stock offering, raises $269.7 million netOct 23FinancingArcus Biosciences, Inc.
Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC dataOct 21Clinical readoutArcus Biosciences, Inc.casdatifanUpdated
Arcus Biosciences discloses preliminary cash estimate in 8-K filingOct 21Quarterly updateArcus Biosciences, Inc.
Arcus Biosciences' ARC-10 lung cancer trial listed as completed as of Oct 2026 updateOct 19Trial updateArcus Biosciences, Inc.domvanalimab
Arcus Biosciences completes Phase 1/1b trial of AB801 in advanced malignanciesOct 9Trial updateAB801Arcus Biosciences, Inc.
Arcus casdatifan: two new trials recruiting, hepatic PK study and RCC gene expression pilotAug 7Weekly roundup, 2 itemsArcus Biosciences, Inc.casdatifan
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca